NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AUPH shares have increased by 9.0% and is now trading at $15.37. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.05. The biotechnology company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 43,965.98% and a negative return on equity of 40.66%. View Aurinia Pharmaceuticals' earnings history.

8 brokers have issued 12 month target prices for Aurinia Pharmaceuticals' shares. Their forecasts range from $14.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $24.29 in the next year. This suggests a possible upside of 58.0% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals.

News articles about AUPH stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a decrease in short interest in April. As of April 30th, there was short interest totaling 4,740,000 shares, a decrease of 5.0% from the April 15th total of 4,990,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 5.5% of the company's shares are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Alibaba Group (BABA), Exelixis (EXEL), Novavax (NVAX) and Corbus Pharmaceuticals (CRBP).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Pictet Asset Management Ltd. (1.44%), Orbimed Advisors LLC (1.19%), Franklin Resources Inc. (1.12%), Connor Clark & Lunn Investment Management Ltd. (0.96%), Assenagon Asset Management S.A. (0.89%) and BlackRock Inc. (0.83%).

AUPH stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ghost Tree Capital LLC, Creative Planning, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., Franklin Resources Inc., and Toronto Dominion Bank.

AUPH stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., Vivo Capital LLC, Wells Fargo & Company MN, Lord Abbett & CO. LLC, Atom Investors LP, and Two Sigma Advisers LP.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $15.37.

Aurinia Pharmaceuticals has a market capitalization of $1.73 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]